Kikuchi Y, Miyauchi M, Iwano I, Kita T, Oomori K, Kizawa I
Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan.
Eur J Cancer Clin Oncol. 1988 Dec;24(12):1829-33. doi: 10.1016/0277-5379(88)90093-4.
Adjuvant effects of prostaglandin D2 to cisplatin on tumor growth were studied by using nude mice bearing HR cells derived from human ovarian carcinoma. Combinations of 0.2 or 0.4 microgram/ml cisplatin and 0.05 or 0.1 microgram/ml prostaglandin D2, which did not affect the HR cell proliferation alone, resulted in a significant inhibition of cell proliferation. In addition, tumor take of HR cells by nude mice in groups treated with a combination of cisplatin and prostaglandin D2 was inhibited. Although there was no significant difference between tumor volumes in mice treated with prostaglandin D2 alone or cisplatin alone and untreated mice, when cisplatin was administered with 1 mg/kg prostaglandin D2 the tumor volume was significantly smaller on days 21 and 35, compared to that of untreated mice. When cisplatin and 2 or 4 mg/kg prostaglandin D2 were combined, the tumor growth was significantly inhibited after day 21, compared not only to that of untreated mice but also of mice treated with cisplatin alone or prostaglandin D2 alone. Such a combination therapy by cisplatin and prostaglandin D2 seemed to result in prevention by prostaglandin D2 of immunological suppression which may be induced by cisplatin. Thus, such a combination therapy brought about a significant prolongation to the survival time.
利用携带源自人卵巢癌的HR细胞的裸鼠，研究了前列腺素D2对顺铂治疗肿瘤生长的辅助作用。单独使用时对HR细胞增殖无影响的0.2或0.4微克/毫升顺铂与0.05或0.1微克/毫升前列腺素D2的组合，导致细胞增殖受到显著抑制。此外，顺铂与前列腺素D2联合治疗组的裸鼠对HR细胞的肿瘤接种率受到抑制。虽然单独使用前列腺素D2或顺铂治疗的小鼠与未治疗的小鼠之间肿瘤体积没有显著差异，但当顺铂与1毫克/千克前列腺素D2联合给药时，在第21天和第35天，肿瘤体积明显小于未治疗的小鼠。当顺铂与2或4毫克/千克前列腺素D2联合使用时，与未治疗的小鼠以及单独使用顺铂或前列腺素D2治疗的小鼠相比，在第21天后肿瘤生长受到显著抑制。顺铂与前列腺素D2的这种联合治疗似乎导致前列腺素D2预防了可能由顺铂诱导的免疫抑制。因此，这种联合治疗显著延长了生存时间。
